Just been looking at the biotech investment landscape heading into late 2026, and there's something interesting emerging here. The sector's been through its cycles, but you've got some solid names trading at valuations that actually make sense right now.

There's this pharmaceutical play that's been catching attention – they've got multiple revenue drivers firing at once. Their flagship anti-inflammatory drug is seeing 34% global sales growth, and their retinal disease treatment is up 66% in the US market alone. On top of that, they're pulling double-digit growth from an oncology immunotherapy program. The company's been steadily expanding earnings, and their pipeline is loaded with late-stage programs across hematology, immunology, and rare disease work. What matters here is that even if only a fraction of their pipeline candidates make it through to market, you're looking at meaningful future growth. The valuation's come down to 17x forward earnings – a significant pullback from the 25x+ levels they were trading at before. For a biotech investment with this kind of product diversity and pipeline depth, that's actually compelling.

Then there's the cystic fibrosis specialist. This company basically owns the CF treatment space with their CFTR modulator drugs – they're addressing 90% of the patient population right now, and they're still working on options for the remaining segment. The IP protection here is strong enough to keep them competitive well into the 2030s. What's really moving the needle though is their expansion beyond CF. They got approval for a gene-editing treatment for blood disorders and a non-opioid pain management option. These new areas could be revenue accelerators over the next few years. They're trading at 24x forward earnings, which for a biotech investment with this kind of market dominance and diversification, looks reasonable.

Both of these companies have that rare combination – proven commercial success with products already generating substantial revenue, plus genuine pipeline potential that could drive the next leg of growth. That's the kind of biotech investment setup worth paying attention to if you're looking to add some pharma exposure to your portfolio in 2026.